WINNIPEG, MANITOBA--(Marketwire - September 03, 2008) - Medicure Inc. (TSX: MPH), a cardiovascular focused, biopharmaceutical company, today announced that new data presented at the annual European Society of Cardiology Congress in Munich, Germany showed AGGRASTAT® (tirofiban HCL) significantly lowers the incidence of heart attack after elective coronary angioplasty in coronary artery disease patients who have shown poor response to standard oral antiplatelet agents, aspirin and clopidogrel. The data comes from a double-blinded study of AGGRASTAT® entitled the 3T/2R Study (Tailoring Treatment with Tirofiban in patients showing Resistance to aspirin and/or Resistance to clopidogrel).
